▶ 調査レポート

ウェアラブルインジェクターのグローバル市場(~2027):身体装着型パッチインジェクター、非身体装着型パッチインジェクター

• 英文タイトル:Wearable Injector Market Research Report by Type, Application, End Use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

360iResearchが調査・発行した産業分析レポートです。ウェアラブルインジェクターのグローバル市場(~2027):身体装着型パッチインジェクター、非身体装着型パッチインジェクター / Wearable Injector Market Research Report by Type, Application, End Use, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19 / MRC2304F186資料のイメージです。• レポートコード:MRC2304F186
• 出版社/出版日:360iResearch / 2022年10月
• レポート形態:英語、PDF、236ページ
• 納品方法:Eメール(受注後2-3日)
• 産業分類:医療機器
• 販売価格(消費税別)
  Single User(1名利用、印刷可)¥742,350 (USD4,949)▷ お問い合わせ
  Enterprise License(企業利用、印刷可)¥1,492,350 (USD9,949)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
360iResearch社の本調査レポートによると、2021年に6,358.74百万ドルであった世界のウェアラブルインジェクター市場規模は2022年に7,057.48百万ドルになり、更に年平均11.16%拡大して2027年までに12,000.44百万ドルに達する見通しです。本書は、ウェアラブルインジェクターの世界市場についての多面的な調査を元に、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別(身体装着型パッチインジェクター、非身体装着型パッチインジェクター)分析、用途別(自己免疫疾患、循環器疾患、糖尿病、感染症、腫瘍)分析、エンドユーザー別(クリニック、在宅医療、病院、オンライン薬局、小売薬局)分析、地域別(南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他)分析、競争状況、企業情報などの内容をまとめた市場調査レポートです。なお、本書に掲載されている企業情報には、Amgen Inc.、BASF SE、Becton, Dickinson and Company、DCA Design International Ltd、E3D Elcam Drug Delivery Devices、Gerresheimer AG、Insulet Corporation、Johnson & Johnson、Medtronic PLC、Neuma LLC、SCHOTT AG、SONCEBOZ SAなどが含まれています。
・序論
・調査方法
・エグゼクティブサマリー
・市場概要
・市場インサイト
・世界のウェアラブルインジェクター市場規模:種類別
- 身体装着型パッチインジェクターの市場規模
- 非身体装着型パッチインジェクターの市場規模
・世界のウェアラブルインジェクター市場規模:用途別
- 自己免疫疾患における市場規模
- 循環器疾患における市場規模
- 糖尿病における市場規模
- 感染症における市場規模
- 腫瘍における市場規模
・世界のウェアラブルインジェクター市場規模:エンドユーザー別
- クリニックにおける市場規模
- 在宅医療における市場規模
- 病院における市場規模
- オンライン薬局における市場規模
- 小売薬局における市場規模
・世界のウェアラブルインジェクター市場規模:地域別
- 南北アメリカのウェアラブルインジェクター市場規模
アメリカのウェアラブルインジェクター市場規模
カナダのウェアラブルインジェクター市場規模
ブラジルのウェアラブルインジェクター市場規模
...
- アジア太平洋のウェアラブルインジェクター市場規模
日本のウェアラブルインジェクター市場規模
中国のウェアラブルインジェクター市場規模
インドのウェアラブルインジェクター市場規模
韓国のウェアラブルインジェクター市場規模
台湾のウェアラブルインジェクター市場規模
...
- ヨーロッパ/中東/アフリカのウェアラブルインジェクター市場規模
イギリスのウェアラブルインジェクター市場規模
ドイツのウェアラブルインジェクター市場規模
フランスのウェアラブルインジェクター市場規模
ロシアのウェアラブルインジェクター市場規模
...
- その他地域のウェアラブルインジェクター市場規模
・競争状況
・企業情報

The Global Wearable Injector Market size was estimated at USD 6,358.74 million in 2021 and expected to reach USD 7,057.48 million in 2022, and is projected to grow at a CAGR 11.16% to reach USD 12,000.44 million by 2027.

Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Wearable Injector to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Type, the market was studied across Body Worn Patch Injector and Off Body Worn Patch Injector.

Based on Application, the market was studied across Autoimmune Disease, Cardiovascular Disease, Diabetes, Infectious Disease, and Oncology.

Based on End Use, the market was studied across Clinic, Home Care Setting, Hospital, Online Pharmacy, Retail Pharmacy, and Specialty Clinics.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Wearable Injector market considering the current update on the conflict and its global response.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Wearable Injector Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Wearable Injector Market, including Amgen Inc., BASF SE, Becton, Dickinson and Company, DCA Design International Ltd, E3D Elcam Drug Delivery Devices, Gerresheimer AG, Insulet Corporation, Johnson & Johnson, Medtronic PLC, Neuma LLC, SCHOTT AG, SONCEBOZ SA, Stevanato Group S.p.A., Valeritas, Inc., West Pharmaceutical Services, Inc., and Ypsomed AG.

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the Global Wearable Injector Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Wearable Injector Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Wearable Injector Market?
4. What is the competitive strategic window for opportunities in the Global Wearable Injector Market?
5. What are the technology trends and regulatory frameworks in the Global Wearable Injector Market?
6. What is the market share of the leading vendors in the Global Wearable Injector Market?
7. What modes and strategic moves are considered suitable for entering the Global Wearable Injector Market?

レポート目次

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of chronic diseases and high demand for advanced drug delivery device
5.1.1.2. Rising demand for minimal invasive treatments
5.1.1.3. Need for subcutaneous and continuous drug delivery
5.1.2. Restraints
5.1.2.1. Low adoption in emerging economies
5.1.3. Opportunities
5.1.3.1. Increasing demand for biologics and mAbs
5.1.3.2. Advancement in injector technology
5.1.4. Challenges
5.1.4.1. Preference for alternative drug delivery modes
5.2. Cumulative Impact of COVID-19

6. Wearable Injector Market, by Type
6.1. Introduction
6.2. Body Worn Patch Injector
6.3. Off Body Worn Patch Injector

7. Wearable Injector Market, by Application
7.1. Introduction
7.2. Autoimmune Disease
7.3. Cardiovascular Disease
7.4. Diabetes
7.5. Infectious Disease
7.6. Oncology

8. Wearable Injector Market, by End Use
8.1. Introduction
8.2. Clinic
8.3. Home Care Setting
8.4. Hospital
8.5. Online Pharmacy
8.6. Retail Pharmacy
8.7. Specialty Clinics

9. Americas Wearable Injector Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Wearable Injector Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Wearable Injector Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Amgen Inc.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. BASF SE
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Becton, Dickinson and Company
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. DCA Design International Ltd
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. E3D Elcam Drug Delivery Devices
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Gerresheimer AG
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Insulet Corporation
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Johnson & Johnson
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Medtronic PLC
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Neuma LLC
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. SCHOTT AG
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. SONCEBOZ SA
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Stevanato Group S.p.A.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Valeritas, Inc.
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. West Pharmaceutical Services, Inc.
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Ypsomed AG
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing